Audit: QRS - Pinitol for Health & Longevity
Audit conducted on 16/08/2026 02:26 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 85 |
| Failed | 0 |
| N/A | 8 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Every populated span traces to ER text: protocol cells to ER Therapeutic Protocol (lines 309, 315, 319), time cells to Practical Considerations (lines 359, 361), benefit/risk items to ER section headings, gate items to Key Interactions & Contraindications (lines 273–291), markers to the ER biomarker table (lines 389–397). |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | marker_9_target carries the ER’s hedge verbatim (“No established target for pinitol response; track change from the individual’s own two-week pre-start baseline”); at_a_glance keeps “nothing has been studied past three months”. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Contraindication strength preserved (“Pregnant or lactating women” remains a stop item, not a caution); at_a_glance retains the negative clamp result rather than reporting only the positive trials. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | stop_items come only from “Populations who should avoid Pinitol”; caution_items only from the six interaction bullets; no Benefit-Modifying Factors or Risk-Modifying Factors content appears in the gates. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, NCT identifiers, author names or supplier brands (Euronutra, Carobway, Vital Nutrients) appear anywhere in the QRS. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No institution, investigator or sponsor is named; trials are referenced generically (“both positive type 2 diabetes trials”, “the fatty liver trial”). |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Measured, conflict-acknowledging register matches the ER Conclusion (“supports curiosity, not confidence”). |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Numeric targets, dose figures and response predictors are given without hype or dismissal. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Content is stated descriptively (e.g., “Split dosing matches the half-life better than once-daily”) rather than as instruction. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No “should”, “must”, “recommend”, “advise” or “consult” appears in the document’s own voice. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | monitoring_cadence is phrased as a described cadence, not a directive; qualitative items are stated as things tracked, not things to do. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronoun occurs; qualitative_item_2 converts the ER’s “note any increase in snacking” to “including any increase in snacking”. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms are limited to biomarker names carried verbatim from the ER table; at_a_glance uses “blood sugar markers” rather than glycemic terminology. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Tier lists are collapsed into single semicolon-separated lines; gate items carry no mitigation or rationale text. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed by full-text scan for second-person forms; none present. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Functional biomarker ranges (fasting insulin 2–5 µIU/mL, HOMA-IR below 1.0) and CGM tracking address an optimization-oriented reader. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Twice-daily meal-timed dosing, a 12-week fasting panel cycle and daily glucose checks are presented without softening for convenience. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | No simplified or reduced-effort alternative protocol is offered. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | at_a_glance and marker_4_why both surface that benefit concentrates in the insulin-resistant phenotype, distinguishing responder from non-responder. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | “anti-aging” does not occur; the title uses “Health & Longevity”. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | Terminology is clinical throughout (alanine aminotransferase, apolipoprotein B, insulin secretagogues); the plain phrasings in at_a_glance are required by 7.4 and mirror the ER Conclusion. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All card, gate and column headings match the template byte-for-byte (lines 440, 477, 519, 537, 549, 567, 582, 586–588, 701); visible tier labels “Medium: “, “Low: “, “Speculative: “ are unmodified. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | Set comparison of all data-qrs-var names shows no template variable missing; the repeatable marker_#_* and qualitative_item_# rows are expanded to 9 and 4 instances respectively. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | website="evidence_review", website="audit" and website="full_review" spans are untouched; a diff of lines 1–409 against the template shows the head, CSS and override link are identical apart from metadata and title. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section that feeds the QRS is empty; absent benefit/risk tiers are handled under 12.5 and 13.5. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | action_1_label “Standard dose”, action_2_label “Single versus split dosing” and action_3_label “Best time of day” reproduce the ER bold labels at lines 309, 319 and 315 verbatim. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Time-cell labels reuse the ER’s own wording from line 359/361; all nine marker names reproduce the ER biomarker table column verbatim. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | Full-text scan returns no emoji code points; the ER’s “⚠️ Conflicted” marker on the Medium benefit was stripped. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Each tier is collapsed to one list item, gate items carry no rationale, and marker “Why” cells are single clauses; no section is expanded beyond the template’s per-section structure. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2–14: the metadata comment immediately follows <!doctype html> on line 1 and precedes the template comment on line 16. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Line 3 opens and line 13 closes the block; the descriptive text “QRS — Metadata (invisible, parsed by audit tooling)” sits before the opening delimiter on line 2. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | The block is a well-formed HTML comment and none of its values are repeated in the header, footer or any span. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:03" is quoted, which is required because the value contains a colon; all other values are bare and untrimmed of nothing. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: pinitol_2026-0825-0025_Opus_ER.md. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.7.02, matching the version badge at the top of QRS.md. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0816-0214, correctly formatted. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” is a single word with no version or qualifier. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” is nickname plus version number with no trailing qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9: qrs_filename: pinitol_2026-0825-0025_Opus_QRS.html, matching the file on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified across all nine keys including git_user: evipedia-1 and git_issue: 5206; no stray whitespace or unnecessary quoting. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: Pinitol for Health & Longevity - Quick Reference Sheet, matching ER canonical_topic with the ampersand encoded. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417: Pinitol for Health & Longevity. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421: 08/16/2026, the correct MM/DD/YYYY rendering of 2026-0816-0214. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: Opus 5, matching the frontmatter value. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | The header block (lines 415–428) contains only the title and the template’s own subline; the ER’s “Also known as” list is not carried over. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Line 433 condenses ER lines 426–428: the compound’s nature, where the human signal sits, the countervailing clamp result, and the safety/duration limit. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 57 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Carob/soybean origin and insulin framing → ER line 426; insulin-resistant signal and null clamp → ER line 426; unremarkable safety and three-month ceiling → ER line 428. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms; “hemoglobin A1c” and “HOMA-IR” are avoided in favor of “longer-term blood sugar markers”, and “insulin clamp” is rendered as “the most rigorous laboratory measurement of insulin sensitivity”. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial name, year, country, sample size or p-value appears. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | Directional language only (“lowered”, “found nothing”); no percentages or absolute changes. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All five items map to the “Populations who should avoid Pinitol” list at ER lines 287–291. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | Lines 540–544 reproduce all five avoid-populations with none omitted and none added. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Each of the five items is a discrete <li> inside the stop_items span. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | The ER’s trailing clauses are all stripped: “— no trial has enrolled either group at any dose”, “, given the untested ovarian D-chiro-inositol hypothesis”, “, since clearance is renal and unstudied in impairment”, “, an age band with no trial data at all”. No dash-led clause remains. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | “(legume)” retained; the renal item keeps both the clinical stage (“stage 4 or worse”) and the threshold “(estimated glomerular filtration rate under 30 mL/min/1.73 m²)”, trimming only the ER’s definitional gloss. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER’s contraindication bullets use no ranking notation inside parentheses. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The ER names five avoid-populations and the section is correctly populated rather than left empty. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All six items map to the interaction bullets at ER lines 273–283. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | Lines 552–557 carry all six interaction bullets; none duplicates a stop_items entry. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Each of the six items is a discrete <li> inside the caution_items span. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | The ER’s “Caution.”/”Monitor.” severity words, mechanistic sentences and “Mitigation:” clauses are all removed; only the agent name and its example list remain. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Every ER drug/example list is preserved: glimepiride/gliclazide/glipizide/repaglinide; high-dose niacin, pseudoephedrine, oral corticosteroids; creatine monohydrate; berberine, chromium picolinate, alpha-lipoic acid, cinnamon extract, myo-inositol, D-chiro-inositol; prolonged fasting, ketogenic diets, endurance exercise blocks. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER’s interaction bullets use no ranking notation inside parentheses. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The ER names six interactions and the section is correctly populated rather than left empty. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells come from ER Therapeutic Protocol: “Standard dose” (line 309), “Single versus split dosing” (line 319), “Best time of day” (line 315). |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Dose, dose schedule and timing are the three executable levers; the remaining ER bullets (competing approach, provenance, half-life, genetics, sex, age, baseline biomarkers, pre-existing conditions) are contextual rather than actionable. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER provides more than three actionable aspects, so all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine spans (lines 444–472) carry substantive ER-sourced content; no placeholder remains. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Fasting glucose/insulin/HOMA-IR, hemoglobin A1c and post-meal glucose are the only three time-to-effect aspects the ER states (line 359). |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Sets 1 and 2 attach to the Medium-tier benefit “Improved Glycemic Control in Insulin-Resistant Type 2 Diabetes”; set 3 attaches to the Low-tier “Attenuated Post-Meal Glucose Excursions”, so the ordering runs Medium → Medium → Low. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER provides three distinct time-to-effect aspects, so all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine spans (lines 483–511) are populated; the subs restate ER lines 359 and 361 without invention. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides time-to-effect information at line 359, so the section is correctly retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All ten entries reproduce ER benefit headings from lines 145–197 with no addition or omission. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans are present at lines 521, 522, 525 and 528. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Only the bare benefit headings are carried; the ER’s Magnitude paragraphs, PubMed links and percentage figures are all dropped. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses remain in any benefit item, and the ER’s “⚠️ Conflicted” annotation on the Medium heading is removed. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | The ER has no High-tier benefit; line 521 renders benefits_high as an empty span with style="display: none" and no empty-state text. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All seven entries reproduce ER risk headings from lines 217–255 with no addition or omission. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans are present at lines 569, 570, 571 and 574. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Only the bare risk headings are carried; the ER’s Magnitude paragraphs and study references are dropped. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses remain in any risk item. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | The ER has no High- or Medium-tier risks; lines 569 and 570 render both spans empty with style="display: none" and no empty-state text. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | All nine rows and the cadence text come from ER Monitoring Protocol & Defining Success (lines 385–397). |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All nine biomarker-table rows are present in the same order: fasting glucose, hemoglobin A1c, fasting insulin, HOMA-IR, alanine aminotransferase, triglycerides, apolipoprotein B, high-sensitivity C-reactive protein, CGM time in range; targets and “why” text are carried verbatim. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Line 695 states the baseline/12-week/six-month schedule plus the daily-check rule for insulin and sulfonylurea users, matching ER line 385. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | All four items come from the “Qualitative markers worth tracking alongside the labs” list at ER lines 401–404. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All four are present in order: post-meal energy stability, hunger and appetite pattern, digestive tolerance, waist circumference. |
Issues 16/08/2026 02:26
Pass rate 100.00%. No issues found.
Issues 16/08/2026 02:20
- 2.6 / 2.9 — Imperative addresses the reader: The Qualitative Assessment bullet [qualitative_item_2] closes with “note any increase in snacking”, an instruction directed at the reader rather than a presentation of evidence.
Fixes 16/08/2026 02:20
- 2.6 / 2.9 — Imperative addresses the reader: Rewrote [qualitative_item_2] from “…ghrelin rise; note any increase in snacking” to “…ghrelin rise, including any increase in snacking”, removing the instruction directed at the reader while keeping the ER-supported content.